- Email: [email protected]
A scrutinized reflection on multiple sclerosis in Middle East countries
316
Abstracts / Journal of the Neurological Sciences 405S (2019) 116542
group and M = 1.8 in the 30–40% working capacity group) or with d850 – Remunerative employment (M = 2.8 and M = 1.6, respectively).
Keywords: Multiple Sclerosis, RRMS, AHSCT
Conclusions The higher the working capacity level of the individual, the fewer the impairment specified by patients in the assessment by ICF categories.
doi:10.1016/j.jns.2019.10.1418
WCN19-1983 doi:10.1016/j.jns.2019.10.1417 Journal of the Neurological Sciences 405S (2019) 105081
WCN19-1978 Journal of the Neurological Sciences 405S (2019) 105080 Poster Session 3 A scrutinized reflection on multiple sclerosis in Middle East countries
Poster Session 3 Therapeutic itinerary of the patients followed for myasthenia in Dakar Y. Kabaa, D. Atsaa, C.C. Affognona, M. Bugemea, S. Mourabitb a Clinique neurosciences Ibrahima Pierre Ndiaye – CHNU Fann, medecine, Dakar, Senegal b Centre Hospitalier National de Pikine, medecine, Dakar, Senegal
V. Jangida, G. Elumalaib, S. Elayarajac, A. Bhonslec a Young Scientific Researcher, Neuroscience, Georgetown, Guyana b Team NeurON, College of Medicine, Texila American University, Neuroscience, Georgetown, Guyana c College of Medicine, Texila American University, Neuroscience, Georgetown, Guyana
Introduction Myasthenia gravis is an autoimmune disease caused by specific autoantibodies that induce dysfunction of neuromuscular transmission. The diagnostic procedure is the same for all patients and at any age. The management starts with the diagnostic, which is often unduly delayed. Our study aims to assess this delay and the associated reasons.
Introduction MS or Multiple Sclerosis is a chronic - progressive disease involving nerve cells sheath of the brain and spinal cord [1]. Recent studies observe the connotation between socioeconomic status (SES) and disability outcomes and progression in MS. The association between SES at MS onset sustained and confirmed Expanded Disability Status Scale (EDSS) 6.0 and 4.0 and onset of secondary progression of MS [2].
Methodology This was a retrospective, cross-sectional and descriptive study over a four years' period from 2014–2017. Data were directly collected from myasthenic patients all coming from the in and outpatient data books of the Fann National University Hospital Center and Department of Pikine National Hospital. A heteroadministered questionnaire was administrated.
Demographic details According to WHO, MS is rapidly increased in the Middle East and North African countries. In 2015, it was observed that the prevalence is 115.94 per 10 thousand population and the women were most affected. A mean age of MS onset is identified as 28.54 yrs. The most common pretentious type of MS in the Middle East were relapsing remitting multiple sclerosis (RRMS) (87.8% in Iran)[3]. Recent advancement According to the recent (2018) evidence, FDA accepted to reevaluate the Cladribine – an immunosuppressant drug for treatment of RRMS [4]. Oral fingolimod is identified as advanced disease modifying therapy against MS, even for pediatric patients [6]. A current (2019) prospective study sought to investigate autologous hematopoietic stem cell transplantation (AHSCT) as a therapeutic intervention in MS.
Results The study included 18 myasthenic, of who 13 women with a ratio of 2.6. With a mean age up to 32 years [14–60 years]. The average time from onset to diagnosis was 24 months. The patients had consulted an average of four times before the diagnosis of myasthenia gravis. The dedicated hospital was attended by 78% of patients and the ophthalmology department was the first consulted in 13 (72%) patients. The mean age of onset was 28 years old. Ptosis was the first symptom in 56% of cases. Conclusion Myasthenia gravis is an unknown affection by the common public and most of the practitioners. The ophthalmologist is often the first resort. The medical practitioner at in and outpatient consultation must be aware of the main symptoms of myasthenia gravis. Keywords: Myasthenia gravis, Therapeutic route, Dakar
Conclusion AHSCT is done to replace the body's immune system so that it no longer attacks the myelin or cause inflammation in a person's brain and spinal cord. Our current study is mainly focus on the quantitative and qualitative analysis of AHSC therapy against MS.
doi:10.1016/j.jns.2019.10.1419
Abstracts / Journal of the Neurological Sciences 405S (2019) 116542
group and M = 1.8 in the 30–40% working capacity group) or with d850 – Remunerative employment (M = 2.8 and M = 1.6, respectively).
Keywords: Multiple Sclerosis, RRMS, AHSCT
Conclusions The higher the working capacity level of the individual, the fewer the impairment specified by patients in the assessment by ICF categories.
doi:10.1016/j.jns.2019.10.1418
WCN19-1983 doi:10.1016/j.jns.2019.10.1417 Journal of the Neurological Sciences 405S (2019) 105081
WCN19-1978 Journal of the Neurological Sciences 405S (2019) 105080 Poster Session 3 A scrutinized reflection on multiple sclerosis in Middle East countries
Poster Session 3 Therapeutic itinerary of the patients followed for myasthenia in Dakar Y. Kabaa, D. Atsaa, C.C. Affognona, M. Bugemea, S. Mourabitb a Clinique neurosciences Ibrahima Pierre Ndiaye – CHNU Fann, medecine, Dakar, Senegal b Centre Hospitalier National de Pikine, medecine, Dakar, Senegal
V. Jangida, G. Elumalaib, S. Elayarajac, A. Bhonslec a Young Scientific Researcher, Neuroscience, Georgetown, Guyana b Team NeurON, College of Medicine, Texila American University, Neuroscience, Georgetown, Guyana c College of Medicine, Texila American University, Neuroscience, Georgetown, Guyana
Introduction Myasthenia gravis is an autoimmune disease caused by specific autoantibodies that induce dysfunction of neuromuscular transmission. The diagnostic procedure is the same for all patients and at any age. The management starts with the diagnostic, which is often unduly delayed. Our study aims to assess this delay and the associated reasons.
Introduction MS or Multiple Sclerosis is a chronic - progressive disease involving nerve cells sheath of the brain and spinal cord [1]. Recent studies observe the connotation between socioeconomic status (SES) and disability outcomes and progression in MS. The association between SES at MS onset sustained and confirmed Expanded Disability Status Scale (EDSS) 6.0 and 4.0 and onset of secondary progression of MS [2].
Methodology This was a retrospective, cross-sectional and descriptive study over a four years' period from 2014–2017. Data were directly collected from myasthenic patients all coming from the in and outpatient data books of the Fann National University Hospital Center and Department of Pikine National Hospital. A heteroadministered questionnaire was administrated.
Demographic details According to WHO, MS is rapidly increased in the Middle East and North African countries. In 2015, it was observed that the prevalence is 115.94 per 10 thousand population and the women were most affected. A mean age of MS onset is identified as 28.54 yrs. The most common pretentious type of MS in the Middle East were relapsing remitting multiple sclerosis (RRMS) (87.8% in Iran)[3]. Recent advancement According to the recent (2018) evidence, FDA accepted to reevaluate the Cladribine – an immunosuppressant drug for treatment of RRMS [4]. Oral fingolimod is identified as advanced disease modifying therapy against MS, even for pediatric patients [6]. A current (2019) prospective study sought to investigate autologous hematopoietic stem cell transplantation (AHSCT) as a therapeutic intervention in MS.
Results The study included 18 myasthenic, of who 13 women with a ratio of 2.6. With a mean age up to 32 years [14–60 years]. The average time from onset to diagnosis was 24 months. The patients had consulted an average of four times before the diagnosis of myasthenia gravis. The dedicated hospital was attended by 78% of patients and the ophthalmology department was the first consulted in 13 (72%) patients. The mean age of onset was 28 years old. Ptosis was the first symptom in 56% of cases. Conclusion Myasthenia gravis is an unknown affection by the common public and most of the practitioners. The ophthalmologist is often the first resort. The medical practitioner at in and outpatient consultation must be aware of the main symptoms of myasthenia gravis. Keywords: Myasthenia gravis, Therapeutic route, Dakar
Conclusion AHSCT is done to replace the body's immune system so that it no longer attacks the myelin or cause inflammation in a person's brain and spinal cord. Our current study is mainly focus on the quantitative and qualitative analysis of AHSC therapy against MS.
doi:10.1016/j.jns.2019.10.1419